Does the media favor EYPT or TXG?

In the previous week, 10x Genomics had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat 10x Genomics' score of 0.77 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or AEHR?

In the previous week, Aehr Test Systems had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Aehr Test Systems and 2 mentions for Eyepoint Pharmaceuticals. Aehr Test Systems' average media sentiment score of 1.11 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Aehr Test Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aehr Test Systems 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNT or EYPT?

In the previous week, Allient had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Allient and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Allient's score of 0.62 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, EYPT or ALMR?

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eyepoint Pharmaceuticals $7.61M 143.48 -$231.96M -$3.50 N/A Alamar Biosciences $87.16M 17.50 N/A N/A N/A

Eyepoint Pharmaceuticals (EYPT) Competitors

$13.03 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$12.56 -0.47 (-3.61%)

As of 06/12/2026 07:30 PM Eastern

Compare

EYPT vs. TXG, AEHR, ALNT, ALMR, and TRNS

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? MarketBeat compares Eyepoint Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eyepoint Pharmaceuticals include 10x Genomics (TXG), Aehr Test Systems (AEHR), Allient (ALNT), Alamar Biosciences (ALMR), and Transcat (TRNS). These companies are all part of the "measuring and control equipment" industry.

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

10x Genomics has a net margin of -3.55% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 10x Genomics' return on equity of -2.86% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
10x Genomics	-3.55%	-2.86%	-2.23%

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

10x Genomics has higher revenue and earnings than Eyepoint Pharmaceuticals. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$7.61M	143.48	-$231.96M	-$3.50	N/A
10x Genomics	$642.82M	5.70	-$43.54M	-$0.17	N/A

Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, suggesting that its share price is 112% more volatile than the broader market.

Eyepoint Pharmaceuticals currently has a consensus target price of $31.80, suggesting a potential upside of 144.05%. 10x Genomics has a consensus target price of $23.17, suggesting a potential downside of 19.67%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, 10x Genomics had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat 10x Genomics' score of 0.77 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

10x Genomics beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Aehr Test Systems (NASDAQ:AEHR) are both measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Aehr Test Systems had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Aehr Test Systems and 2 mentions for Eyepoint Pharmaceuticals. Aehr Test Systems' average media sentiment score of 1.11 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Aehr Test Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aehr Test Systems	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, Aehr Test Systems has a beta of 3.18, suggesting that its stock price is 218% more volatile than the broader market.

Aehr Test Systems has higher revenue and earnings than Eyepoint Pharmaceuticals. Aehr Test Systems is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$7.61M	143.48	-$231.96M	-$3.50	N/A
Aehr Test Systems	$58.97M	57.85	-$3.91M	-$0.38	N/A

Aehr Test Systems has a net margin of -25.23% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Aehr Test Systems' return on equity of -7.15% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Aehr Test Systems	-25.23%	-7.15%	-6.15%

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Aehr Test Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals presently has a consensus price target of $31.80, suggesting a potential upside of 144.05%. Aehr Test Systems has a consensus price target of $68.00, suggesting a potential downside of 37.31%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Aehr Test Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aehr Test Systems beats Eyepoint Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Allient?

Allient (NASDAQ:ALNT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Allient currently has a consensus price target of $77.33, indicating a potential downside of 15.36%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, indicating a potential upside of 144.05%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Allient has a net margin of 4.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Allient's return on equity of 12.47% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

61.6% of Allient shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 15.0% of Allient shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Allient has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

Allient has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	2.80	$22.03M	$1.43	63.90
Eyepoint Pharmaceuticals	$7.61M	143.48	-$231.96M	-$3.50	N/A

In the previous week, Allient had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Allient and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Allient's score of 0.62 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Allient beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$7.61M	143.48	-$231.96M	-$3.50	N/A
Alamar Biosciences	$87.16M	17.50	N/A	N/A	N/A

Alamar Biosciences has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Alamar Biosciences' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Alamar Biosciences	N/A	N/A	N/A

Eyepoint Pharmaceuticals presently has a consensus price target of $31.80, suggesting a potential upside of 144.05%. Alamar Biosciences has a consensus price target of $30.00, suggesting a potential upside of 36.36%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.87 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Positive
Alamar Biosciences	Very Positive

Summary

Eyepoint Pharmaceuticals beats Alamar Biosciences on 7 of the 12 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Transcat?

Transcat (NASDAQ:TRNS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

98.3% of Transcat shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Transcat. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Eyepoint Pharmaceuticals' score of 0.93 indicating that Transcat is being referred to more favorably in the media.

Company	Overall Sentiment
Transcat	Positive
Eyepoint Pharmaceuticals	Positive

Transcat has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.57	$5.38M	$0.58	157.34
Eyepoint Pharmaceuticals	$7.61M	143.48	-$231.96M	-$3.50	N/A

Transcat has a net margin of 1.62% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Transcat's return on equity of 5.84% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Transcat has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the broader market.

Transcat presently has a consensus target price of $105.33, suggesting a potential upside of 15.42%. Eyepoint Pharmaceuticals has a consensus target price of $31.80, suggesting a potential upside of 144.05%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Eyepoint Pharmaceuticals beats Transcat on 9 of the 17 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09B	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-3.72	20.00	24.00	24.42
Price / Sales	143.48	304.30	514.65	112.54
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	3.52	8.32	10.69	6.82
Net Income	-$231.96M	$23.94M	$3.57B	$337.56M
7 Day Performance	13.80%	1.84%	0.61%	1.16%
1 Month Performance	5.51%	-0.04%	1.56%	3.16%
1 Year Performance	44.30%	44.82%	25.44%	30.60%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.7625 of 5 stars	$13.03 flat	$31.80 +144.1%	+44.3%	$1.09B	$7.61M	N/A	120	Positive News
TXG 10x Genomics	1.9131 of 5 stars	$29.42 +0.8%	$23.17 -21.2%	+177.0%	$3.71B	$642.82M	N/A	1,240	Gap Up
AEHR Aehr Test Systems	1.965 of 5 stars	$90.30 -5.5%	$68.00 -24.7%	+858.2%	$2.82B	$58.97M	N/A	90	Positive News Gap Down
ALNT Allient	2.8562 of 5 stars	$85.54 -1.9%	$77.33 -9.6%	+170.1%	$1.44B	$560.59M	59.18	2,478	Analyst Upgrade Gap Up
ALMR Alamar Biosciences	4.7592 of 5 stars	$19.32 +0.6%	$30.00 +55.3%	N/A	$1.34B	$87.16M	N/A	222

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. TXG, AEHR, ALNT, ALMR, and TRNS

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Summary

How does Eyepoint Pharmaceuticals compare to Transcat?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. TXG, AEHR, ALNT, ALMR, and TRNS

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Is EYPT or TXG more profitable?

Do institutionals & insiders have more ownership in EYPT or TXG?

Which has better earnings and valuation, EYPT or TXG?

Which has more volatility and risk, EYPT or TXG?

Do analysts recommend EYPT or TXG?

Does the media favor EYPT or TXG?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Does the media favor EYPT or AEHR?

Which has more volatility & risk, EYPT or AEHR?

Which has preferable earnings and valuation, EYPT or AEHR?

Is EYPT or AEHR more profitable?

Do insiders and institutionals have more ownership in EYPT or AEHR?

Do analysts prefer EYPT or AEHR?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Do analysts recommend ALNT or EYPT?

Is ALNT or EYPT more profitable?

Do institutionals & insiders believe in ALNT or EYPT?

Which has more risk and volatility, ALNT or EYPT?

Which has higher earnings & valuation, ALNT or EYPT?

Does the media prefer ALNT or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Which has preferable valuation and earnings, EYPT or ALMR?

Is EYPT or ALMR more profitable?

Do analysts prefer EYPT or ALMR?

Do institutionals & insiders have more ownership in EYPT or ALMR?

Does the media favor EYPT or ALMR?

Summary

How does Eyepoint Pharmaceuticals compare to Transcat?

Do institutionals and insiders hold more shares of TRNS or EYPT?

Does the media refer more to TRNS or EYPT?

Which has better earnings & valuation, TRNS or EYPT?

Is TRNS or EYPT more profitable?

Which has more volatility & risk, TRNS or EYPT?

Do analysts prefer TRNS or EYPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools